Red and near-infrared light therapy (photobiomodulation) has been studied for decades in humans and animals. Here are key findings from peer-reviewed canine research.
Looney et al., 2018
36 pets · Cornell University · Peer-reviewed
In a randomized, blinded, placebo-controlled trial of dogs with elbow osteoarthritis, 82% of dogs receiving PBM achieved a 50%+ reduction in NSAID requirements over 6 weeks. 9 of 11 treated dogs showed measurable improvement vs. 0 of 9 in the sham group.
P = 0.0003
Barale et al., 2023
Accelerometer-monitored · Objective measurement
Dogs with osteoarthritis nearly doubled their daily physical activity over 6 weeks of PBM therapy — from a mean of 93,481 steps to 179,309 steps. This represents objective, measurable improvement in mobility.
+91% daily activity
Hoisang et al., 2021
Post-surgical recovery · Multi-wavelength
The multi-wavelength PBM group (660nm + 875nm + 905nm) achieved 61.8% wound area reduction compared to 42.4% in controls within 15 days — supporting 46% faster natural recovery.
P < 0.05
Alves et al., 2022
Systematic review · Double-blinded RCT
PBM provided superior comfort scores and faster return to baseline gait function compared to meloxicam (a standard NSAID) in dogs with hip osteoarthritis.
Superior to NSAID
Our Wavelengths
The Revival Mat uses 660nm (red) + 850nm (near-infrared) at a 1:2 ratio. These are the most studied wavelengths in photobiomodulation research, and the same wavelengths used in veterinary clinic devices.
Lab Verification
Our wavelength output is independently verified by EVERFINE, a third-party photometry laboratory. We publish our lab results because most companies won't.
Results may vary. Studies referenced describe photobiomodulation research broadly, not this specific device. Not intended to diagnose, treat, cure, or prevent any disease.